期刊文献+

组蛋白去乙酰酶抑制剂的药理学研究进展 被引量:2

Advances in pharmacological study of histone deacetylase inhibitors
下载PDF
导出
摘要 组蛋白的乙酰化调节,参与了基因表达的调控;组蛋白乙酰转移酶和组蛋白去乙酰酶活性共同决定了组蛋白的乙酰化水平。组蛋白去乙酰酶抑制剂可提高组蛋白的乙酰化水平,并对一些非组蛋白成分产生影响,从而调节某些特定基因的表达。综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。 Acetylation of histone involves in the regulation of gene expression. The level of his-tone acetylation is determined by the activities of histone acetyltransferases and histone deacetylases. Histone deacetylase inhibitors increase the acetylation level of histone as well as some non-histone proteins , and specifically modulate some gene expression. The pharmacological actions of histone deacetylase inhibitors and their potential clinical uses were reviewed.
出处 《中国新药杂志》 CAS CSCD 北大核心 2004年第7期594-598,共5页 Chinese Journal of New Drugs
关键词 组蛋白乙酰转移酶 酶抑制剂 基因表达 肿瘤 histone deacetylases enzyme inhibitors gene expression cancer
  • 相关文献

参考文献36

  • 1[1]Timmermann S, Lehrmann H, Polesskaya A, et al. Histone acetylation and disease[J]. Cell Mol Life Sci ,2001,58(5 - 6):728 - 736.
  • 2[2]Roth SY, Denu JM, Allis CD. Histone acetyltransferases[ J ]. Annu Rev Biochem ,2001,70(1): 81 - 120.
  • 3[3]Sterner DE, Berger SL. Acetylation of histones and transcription-related factors[J]. Microbiol Mol Biol Rev ,2000,64(2) :435 -459.
  • 4[4]Janknecht R. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease [ J ]. Histol Histopathol, 2002,17(2): 657 - 668.
  • 5[5]Johnson CA, Turner BM. Histone deacetylases: complex transducers of nuclear signals[J]. Semin Cell Dev Biol, 1999,10(2):179- 188.
  • 6[6]De Ruijter AJ, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family[ J ]. Biochem J, 2003,370 (3): 737 - 749.
  • 7[7]Minucci S, Nervi C, Lo CF, et al. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? [ J ]. Oncogene, 2001, 20 ( 24 ): 3110 -3115.
  • 8[8]Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds[J]. J Cell Sci ,2001,114(13):2363 - 2373.
  • 9[9]Hsssan AH, Neely KE, Vignali M, et al. Promoter targeting of chromatin-modifying complexes [ J ]. Front Biosci, 2001, 6:D1054 - D1064.
  • 10[10]Hassig CA, Schreiber SL. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs [ J ].Curr Opin Chem Biol, 1997,1 (3): 300 - 308.

同被引文献31

  • 1马华智,吴纯启,廖明阳.羟基脲的非临床分子毒理学研究进展[J].癌变.畸变.突变,2004,16(5):318-320. 被引量:5
  • 2黄轶群,马旭东.组蛋白乙酰化与白血病[J].白血病.淋巴瘤,2006,15(2):145-148. 被引量:2
  • 3唐丽琴,魏伟.组蛋白去乙酰化酶抑制剂与炎症免疫性疾病[J].中国药理学通报,2007,23(1):1-4. 被引量:5
  • 4王洁,王治平.儿童脊肌萎缩症诊治新进展[J].诊断学理论与实践,2007,6(3):281-283. 被引量:2
  • 5Mitchell RL,Ching HW.Spinal muscular atrophy[J].The Lancet,2008,71(9630):2121-2133.
  • 6Alea D,Erkan O,Christion LL.A negatively acting bifunction RNA increase survival motor neuron both in vitro and in vivo[J].Human Gene Therapy,2008,19(11):1307-1315.
  • 7Dimatteo D,Calahan S,Kmiec EB.Genetic conversion of an SMN2 gene to SMN1:a novel approach to the treatment of spinal muscular atrophy[J].Exper Cell Res,2008,314:878-886.
  • 8Lisziewicz J,Foli A,Lori WM.Hydroxyurea in the treatment of HIV infection:clinical efficacy and safety concerns[J].Drug Sa,2003,26(9):605-624.
  • 9Chung YY,Hui HL,Ya SC,et al.5-(N-ethy-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells[J].Ann Neurol,2008,63:26-34.
  • 10Nathalie C,Salima HBA,Cynthia CB,et al.Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy[J].Science,2009,326(5954):818-823.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部